Citi Pharma acquires 20% stake in Pakheim International
Mettis Global • • 1 min read
Mettis Global reported on October 30, 2026 that Citi Pharma Limited (PSX: CPHL) acquired a 20 per cent holding in Pakheim International Pharma (Private) Limited. The purchase is being made under an agreement signed on May 6, 2026, and Citi Pharma disclosed it to the Pakistan Stock Exchange as material information.
The 20 per cent stake is the initial tranche of Citi Pharma’s previously announced plan to acquire all of Pakheim International Pharma. The company intends to buy the remaining shares under the agreement, subject to completion of the required formalities. Citi Pharma said it will provide the exchange with further material updates in line with regulatory requirements; its disclosure does not say that the remaining acquisition has been completed.
At a glance
- Citi Pharma acquired a 20 per cent stake in Pakheim International Pharma.
- The stake is the first part of a proposed acquisition of the entire company.
- The remaining purchase is subject to agreement terms and required formalities.
Stocks in this story
Originally reported by Mettis Global
This page is Investify's own summary. The full report, with all details and context, is on the publisher's site.
Read the full storyWant the full article here?
Log in to read the full article in the Investify reader, in English or Urdu.
Investify summarizes Pakistan Stock Exchange news in its own words and links each story to its original publisher. We always credit the source so you can read the full report and verify the details before making financial decisions.
More on CPHL
CCP allows Citi Pharma to acquire PakheimBR• 20 Oct 2026Neutral coverage
Citi Pharma secures CCP approval to acquire 100% stake in Pakheim International PharmaProfit• 19 Oct 2026Positive coverage- Citi Pharma gets CCP Nod for 100% acquisition of Pakheim International PharmaMettis• 19 Oct 2026Positive coverage
Citi Pharma receives CCP nod to acquire Pakheim InternationalBR• 19 Oct 2026Positive coverage- CPHL FY26 profit softens 11%Mettis• 5 Oct 2026Negative coverage
- Citi Pharma gets shareholder nod to alter memorandum for cannabis businessMettis• 18 Sept 2026Neutral coverage
